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ABSTRACT  1 
Background & Aims: Serum lipids and lipoproteins are established biomarkers of cardiovascular 2 
disease risk that could be influenced by impaired gut barrier function via effects on the absorption of 3 
dietary and biliary cholesterol. The aim of this study was to examine the potential relationship 4 
between gut barrier function (gut permeability) and concentration of serum lipids and lipoproteins, in 5 
an ancillary analysis of serum samples taken from a previous study.   6 
Methods and Results: Serum lipids, lipoproteins and functional gut permeability, as assessed by the 7 
percentage of the urinary recovery of 51-Cr-labelled EDTA absorbed within 24h, were measured in a 8 
group of 30 healthy men.  Serum lipopolysaccharide, high sensitivity C-reactive protein and 9 
interleukin-6 were also measured as markers of low-grade inflammation.  The group expressed a 5-10 
fold variation in total gut permeability (1.11 - 5.03%). Gut permeability was unrelated to the 11 
concentration of both serum total and low density lipoprotein (LDL)-cholesterol, but was positively 12 
associated with serum high density lipoprotein (HDL)-cholesterol (r=0.434, P=0.015). Serum HDL-13 
cholesterol was also positively associated with serum endotoxaemia (r=0.415, p=0.023).   14 
Conclusion: The significant association between increased gut permeability and elevated serum 15 
HDL-cholesterol is consistent with the role of HDL as an acute phase reactant, and in this situation, 16 
potentially dysfunctional lipoprotein. This finding may have negative implications for the putative 17 
role of HDL as a cardio-protective lipoprotein. 18 
  19 
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INTRODUCTION 1 
Impaired gut barrier function resulting from increased gut permeability (‘leaky gut’), is a condition in 2 
which the intestinal barrier is physically breached by insults that disrupt tight junctions, causing a 3 
translocation of luminal contents, including bacteria and bacterial endotoxins e.g. lipopolysaccharides 4 
(LPS), that can produce a low grade systemic inflammation (1, 2). While these phenomena have been 5 
described almost exclusively in animal models (3), they have been reported by us in patients with 6 
type-2 diabetes (4), and by others in obesity, metabolic syndrome and the pathogenesis of other 7 
human diseases (5, 6).   8 
Raised serum LDL-cholesterol and low serum HDL-cholesterol (< 1mmol/L), are established 9 
biomarkers of increased CVD risk (7), though whether raising HDL reduces CVD risk is still not 10 
clear, since the cardio-protective role of HDL depends on its functional capacity to prevent 11 
atherosclerosis, and not on its cholesterol content (8). The concentration of serum LDL-cholesterol is 12 
regulated, in part, by a reciprocal cross-talk between the intestinal absorption of dietary and biliary 13 
cholesterol, and hepatic biosynthesis of cholesterol (9). The absorption of cholesterol in the gut lumen 14 
is regulated by transport proteins in the apical cell membrane of enterocytes that control the influx and 15 
efflux of cholesterol. This mechanism is sensitive to the quantity of cholesterol in the gut lumen, and 16 
is down-regulated as the content of cholesterol in the gut lumen increases (10, 11).  One possible 17 
effect of this mechanism is to limit the supply of cholesterol, chiefly to the liver, which could 18 
upregulate the cellular uptake of LDL, and lower serum LDL-cholesterol.  19 
We hypothesised that increased intestinal paracellular permeability could disrupt cholesterol 20 
homeostasis by interfering with the feedback suppression of dietary and biliary cholesterol absorption 21 
in the gut, which normally serves as a mechanism to prevent an oversupply of cholesterol for 22 
lipoprotein synthesis. It is also possible that local inflammation could affect the balance of cholesterol 23 
transport into and out of enterocytes via the down-regulation of cholesterol efflux proteins (ABCA1, 24 
ABC G1), as seen in macrophages treated with bacterial endotoxins (12). These effects could manifest 25 
as an increase in serum LDL-cholesterol in response to the altered absorption of cholesterol in the gut 26 
lumen. Low grade systemic inflammation associated with bacterial LPS-induced endotoxaemia has 27 
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also been linked to reduced serum HDL-cholesterol and the production of dysfunctional HDL, in 1 
metabolic syndrome, type-2 diabetes, and chronic arthritis (13-15). The purpose of this study was to 2 
determine whether variation in gut barrier function is related to the concentration of serum lipids and 3 
lipoproteins in normal healthy men, at low risk of CVD. 4 
  5 
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METHODS 1 
Design: A cross-sectional study to evaluate possible links between gut permeability and serum lipids 2 
and lipoproteins, by the secondary analysis of serum samples from healthy men who acted as controls 3 
in a previous study in diabetes (16). The original protocol was approved by the Central London NRES 4 
Committee (REC reference no. 11/LO/1141) and the University of Surrey Ethics Committee, and was 5 
conducted according to the declaration of Helsinki. 6 
Study Population: Thirty men, mean age 56 years (range 43-67 years) were recruited through 7 
primary care and volunteer databases at the University of Surrey.  All subjects provided written 8 
informed consent. Exclusion criteria included use of antibiotics in the previous three months, use of 9 
anti-inflammatory medications, diuretics, proton-pump inhibitors, inflammatory bowel disease, 10 
Crohn’s disease, coeliac disease, irritable bowel disease or a positive family history of type 2 diabetes. 11 
Prior renal function was assessed to ensure suitability for the  administration of a radioisotope (eGFR 12 
> 60 mL/min/1.73 m2) (17). The cohort included men who were obese (n=3), over weight (n=13) and 13 
normal body weight (n=14).  The cardio-metabolic risk of participants was assessed by a scoring 14 
system based on a modified version of the Adult Treatment Panel III guidelines, as previously 15 
described for the 'RISCK' study in healthy men aged 30-70 years.  The mean cardio-metabolic risk 16 
score, as a measure of predisposition to the development of metabolic syndrome (≥4), was 1.5 (range 17 
0-6) (18).   18 
Blood pressure, anthropometrics and biochemistry: Body weight, body mass index (BMI) and 19 
body composition were measured by bio-impedance (Tanita, Arlington Heights, IL, USA), following 20 
a 10 hour overnight fast and emptying of the bladder. Waist circumference was measured at the level 21 
of the umbilicus. After 5 minutes rest, blood pressure was determined as the mean of three readings 22 
(Omron MX3 Plus, Omron Healthcare Europe, Milton Keynes, United Kingdom). Blood was taken 23 
from an ante-cubital vein and collected into serum tubes containing EDTA and clotting activator, and 24 
pyrogen free tubes for measurement of serum biomarkers of inflammation, lipids and LPS. Blood 25 
samples were centrifuged at 3000 x g at 4°C for 10 minutes and serum and plasma stored at -20°C or -26 
80°C as appropriate. 27 
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Dietary intakes: This was assessed by a 7-day diet diary. Subjects were instructed to avoid probiotic 1 
food items, fermented foods such as yogurt, soft cheese, kimchi, in addition to prebiotic/probiotic 2 
supplements for two weeks before the test day. Diet diaries were analysed by a single operator, using 3 
DietPlan6 (Forestfield Software Ltd, Horsham, UK).  4 
 5 
Intestinal permeability: Intestinal permeability was functionally assessed by the 24h urinary 6 
excretion of orally administered 51Cr-EDTA, as previously described (4, 16, 17, 19). The 51Cr-EDTA 7 
tracer was administered after an overnight fast, after which, participants were asked to collect all of 8 
their urine for the next 24 hours. The urine was collected into one container for the first 6 hours and 9 
into a separate container between 6-24 hours. The percentage recovery 51Cr-EDTA between 0-6h and 10 
6-24h was taken as a measure of gut permeability in the small and large intestine, respectively. The 11 
total permeability of the gut was taken as the 0-6 and 6-24h samples combined. 12 
Biochemical Analyses: Serum high sensitivity C-reactive protein (hsCRP) was measured by an 13 
accredited laboratory (The Surrey Pathology Partnership), interleukin-6 (IL-6) and tumour necrosis 14 
factor-α (TNF-α) were measured in-house, using a Luminex platform and Biorad bio-plex kits and 15 
software. The limit of detection were 0.03mg/l for hsCRP, 5 pg/mL for TNF-α and 0.7pg/ml for IL-6 16 
with average intra-assay CVs were 1.4%, 0.6% and 1.0%, respectively.  Plasma triglycerides (TG), 17 
total cholesterol, HDL cholesterol, and non-esterified fatty acids (NEFA) were measured on an 18 
ILab650, using commercially available kits (Randox Laboratories, UK, and Instrumentation 19 
Laboratory, UK). Mean intra-assay CVs were 1.4%, 1.9%, 0.6% and 1.0% and inter-assay CVs were 20 
1.9%, 3.0%, 1.1% and 1.8% for TG, total cholesterol, HDL-cholesterol, and NEFA, respectively. 21 
Serum LDL-cholesterol was calculated using the Friedewald formula. Serum LPS was measured in 22 
duplicate using Endosafe-MCS (Charles River Laboratories, Lyon, France), as previously described 23 
(20). Samples were diluted from 1/20 to 1/200 and validated for recovery using positive product 24 
control (PPC) samples to account for sample losses due to interfering factors. The recovery value of 25 
the PPC samples was 70-150% and the %CV for the PPC and serum samples was <25%. This level is 26 
above that validated by the FDA for LPS quantification. Serum LPS binding protein (LBP) and 27 
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sCD14 concentrations were measured using a solid-phase enzyme-linked immunosorbent assays 1 
according to the manufacturer’s instructions (Hycult Biotechnology, Uden, the Netherlands). Sera 2 
were diluted 1/10 with the appropriate buffer and homogenized by vortex before further dilution to 3 
1/200 (sCD14) and 1/1000 (LBP). The detection limits were 4.4 and 1.56 ng/mL and the average 4 
intra-assay CVs were 3.9% and 8.5%, and inter-assay CVs were 19.6% and 15.5% for LBP and 5 
sCD14, respectively.  6 
Statistical analysis  7 
Associations between normally distributed anthropometric data, metabolic parameters and serum 8 
lipoproteins in the whole group, were examined by calculating Pearson’s product moment correlation 9 
coefficients (r) on raw data. Associations with serum LPS were determined using Spearman’s 10 
coefficient of rank correlation. Univariate associations between anthropometric, metabolic and dietary 11 
variables were examined by a univariate linear regression model, with HDL-cholesterol as the 12 
dependent variable. The group was also subdivided into two groups on the basis of serum HDL-13 
cholesterol being above, and below or equal to 1 mmol/L, a clinically recognised cut-off that 14 
discriminates CVD risk associated with HDL-cholesterol (21). Between-group differences for 15 
normally distributed data were compared using an independent sample t-test, with correction for 16 
multiple parameter testing. The distribution of serum LPS was not normally distributed and could not 17 
be normalised by log transformation, so these data were analysed using a Mann-Whitney U test. A 18 
probability level of ≤ 5% was considered significant.  19 
  20 
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RESULTS 1 
Gut permeability of the large and small intestine combined, showed a greater than 5-fold difference 2 
across the group (1.11 to 5.03%). Gut permeability was unrelated to body weight, BMI, serum 3 
biomarkers of inflammation and plasma total cholesterol. In contrast, plasma HDL-cholesterol was 4 
correlated with intestinal permeability in both the small and large intestine (r= 0.390, P=0.032; 5 
r=0.370, P= 0.043; Figure 1A).  Gut permeability of the small intestine was also significantly 6 
correlated with serum TG (r=-0.386, P= 0.035). There was a trend for an association between serum 7 
LDL-cholesterol and gut permeability in the small intestine (r= -0.354, P=0.078, Figure 1B), and 8 
evidence of a much wider distribution of serum TG values at a gut permeability level of less than 9 
1.5% (Figure 1C). 10 
The group expressed a broad range of plasma lipid and lipoprotein concentrations, the mean values of 11 
which fell below clinically recognised action limits for these variables (Table 1). There were also 12 
subgroups with LDL-cholesterol that would be considered ‘borderline high, to high and undesirable’ 13 
(3.4 - 4.1mmo/l, n=15/30) and ‘very high’ (>4.9mmol/l, n=3/30). The serum concentration of 14 
inflammatory biomarkers were also within their normal reference ranges, however, serum LPS and 15 
HDL were highly correlated in the whole group (Figure 2B). Subdivision of the group on the basis of 16 
a plasma HDL-cholesterol above and below 1mmol/L, a clinically recognised threshold, below which 17 
CVD risk is increased significantly (Table 1), also showed serum LPS to be higher in men with raised 18 
HDL-cholesterol (P=0.023, Figure 2A). Subdivision of the group also strengthened the significance 19 
of the associations between HDL-cholesterol and total, small and large intestinal permeability. All of 20 
the directly measured (rather than calculated) variables were examined together by univariate linear 21 
regression (Table 2). After adjustment for the other variables, the relationship between HDL-22 
cholesterol and the 0-6 h recovery of urinary 51Cr-EDTA and serum LPS remained significant at 23 
p=0.004 and p=0.036, respectively.  24 
The mean recorded dietary intakes for the group failed to meet current UK E% dietary 25 
recommendations for total carbohydrate (42.4 ± 1.46% vs > 50%), non-milk extrinsic sugars (18.3 ± 26 
1.29% vs <11%), total fat (37.5 ± 1.62% vs <35%), saturated fat (13.6 ± 0.69% vs <11%), and total 27 
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dietary fibre (10.4 ± 0.56g vs ≥30g) (22). The protein intake for the group was 14.8 ± 0.48 E%, 1 
although it was not possible to differentiate between animal and plant sources. There were significant 2 
positive correlations between total protein intake and markers of inflammation (LPS r=0.427, 3 
P=0.019; hsCRP r=0.567, P=0.001; and sCD14 r=0.581, P=0.001). Mean alcohol intake for the group 4 
was 13.6 ± 1.68g/day (individuals initially reporting intakes of alcohol at recruitment above the then 5 
UK guideline recommendation of 21 units (24g alcohol/day) were excluded from the study). Alcohol 6 
intake was also correlated with increased markers of inflammation even at the modest levels reported, 7 
(hsCRP r=0.445, P=0.015; and sCD14 r=0.442, P=0.016). There were no significant differences in 8 
dietary intakes between low and high HDL-cholesterol groups or any bivariate correlations with 9 
HDL-cholesterol. However, total carbohydrate, protein and fat were associated with HDL-cholesterol 10 
in univariate analysis (Table 2). The mean reported energy intake for the group was 9.8 ± 0.36 11 
MJ/day with a mean Reported EnergyINTAKE: BMR of 1.4 (SEM 0.06) as an index of under-reporting, 12 
using predicted BMR (23).  13 
  14 
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DISCUSSION   1 
Increased gut permeability/impaired gut barrier function, secondary to dysbiosis, is emerging as an 2 
early underlying cause of metabolic diseases that may be associated with weight gain and obesity 3 
through overfeeding, most notably with dietary fat (24).  Abnormally high gut permeability (≥ 2.5%), 4 
at levels typically associated with coeliac disease (active > ~4.7%;  in remission >~3.0% (25)), 5 
inflammatory bowel disease (>~3.47% (26)), non-alcoholic fatty liver disease (NAFLD > ~3.14% 6 
(27)) and type 2 diabetes (> ~3.60%) (4), has been linked to the susceptibility of developing these 7 
diseases. To the best of our knowledge, the present study provides the first evidence for marked 8 
variability in normal gut-barrier function, as measured by differences in gut permeability in vivo in 9 
men, without current or family history of diabetes or gastrointestinal disease.  10 
The underlying rationale for this study was that gut barrier function may be linked to the 11 
concentration of serum lipoproteins, and specifically LDL-cholesterol, by influencing the absorption 12 
of dietary and biliary cholesterol. However, there was no evidence from the wide distribution of 13 
variables to suggest that increased gut permeability or serum LPS were related to serum LDL-14 
cholesterol. While this finding comes with the caveat that the sample size in this ancillary analysis 15 
limited the statistical power, calculated retrospectively as 61% (2-sides, α 0.05), it suggests that 16 
barrier function was not compromised, at least to an extent that could produce adverse effects on 17 
cholesterol homeostasis in the gut. In contrast, increased gut permeability and serum LPS were 18 
unexpectedly associated with elevated plasma HDL-cholesterol, even with the sample size limitation. 19 
This finding could be viewed as paradoxical, in that impaired barrier function and local systemic 20 
inflammation are commonly found in obesity, metabolic syndrome and type-2 diabetes (1-3), all of 21 
which are characterised by a low HDL-cholesterol. Indeed, studies in those with confirmed metabolic 22 
diseases such as type 2 diabetes and NAFLD, report an inverse relationship between serum zonulin 23 
(modulates intestinal permeability by disassembling intercellular tight junctions between epithelial 24 
cells (28)) and HDL-cholesterol (29, 30). However, it should be noted that in our study the 51Cr-25 
EDTA test represents a functional measure of paracellular permeability only and that other 26 
biomarkers such as serum zonulin and diamine oxidase (DAO) (31) or faecal levels of alpha-1-27 
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antitrypsin and albumen which have all been shown to correlate with functional intestinal 1 
permeability, as reviewed by (32), may have added further information on the mechanism and/or site 2 
of the disruption.. The use of inert probes to assess functional permeability has the advantage in that 3 
recovery is complete as the label is not metabolised or sequestered, however recovery would be 4 
affected by human factors such as delayed gastrointestinal motility or a reduced mucosal blood flow. 5 
In healthy individuals this may be less of a confounder than in gastrointestinal disease patients. In the 6 
future DAO would need to be used as more specific marker of small intestinal integrity, as in the gut, 7 
the enzyme is localised to the tip of the enterocyte villi. 8 
 9 
Since our observation was in men with a wide range of serum cholesterol levels, the associations with 10 
elevated HDL might represent a distinct, subclinical phenomenon, that is expressed at the upper end 11 
of the range of gut permeability. A positive association between HDL-cholesterol and intestinal 12 
permeability has been reported recently in pregnant women (33). While this finding was linked 13 
specifically to maternal lipid metabolism, it provides further evidence in support of this association 14 
being an in vivo phenomenon in otherwise healthy individuals.  15 
 16 
Up to 30% of the steady-state serum HDL-cholesterol pool may be derived from the small intestine, 17 
but whether the contribution of this gut-derived HDL-cholesterol confers any benefit to 18 
cardiovascular health is unknown, since this will depend on the functional properties of HDL in 19 
preventing cardiovascular atherosclerosis, and not on the serum concentration of HDL-cholesterol.  20 
Serum HDL-cholesterol was first established as a discriminating biomarker of CVD risk in large 21 
prospective cohort studies in the 1970s, with a concentration of HDL-cholesterol below 1mmol/L 22 
being used subsequently as a metric to forecast the 10 year risk of suffering a cardiovascular event 23 
(21).  Conversely, there is much less evidence that raising serum HDL-cholesterol reduces CVD risk, 24 
primarily because not all HDL is equivalent in its functional capacity to confer protection against 25 
CVD (8).  Intestinal permeability regulates molecular trafficking between the intestinal lumen and the 26 
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submucosa, and high levels of cytokines further contribute to intestinal barrier dysfunction by altering 1 
the structure and localisation of tight junctions (34). The gut lumen is a prominent source of persistent 2 
immune-stimulation which can result in sub-clinical mucosal inflammation through the transfer of 3 
LPS and other bacterial products (3). The significant associations between increased gut permeability, 4 
gut-derived LPS and plasma HDL-cholesterol in the present study, suggest that the elevated HDL may 5 
be an acute phase reactant, produced in response to local inflammation in the gut, since its principal 6 
apoprotein, apo A-I, is synthesised in the gut and recognised as an acute phase protein (15). Low 7 
doses of LPS (3ng/kg) given to humans have been shown to increase acute phase proteins e.g. serum 8 
amyloid A (SAA), CRP, apo A-I.  In mammals, SAA is the major acute phase reactant that is 9 
transported in serum HDL. Increased SAA in HDL under inflammatory conditions has been 10 
implicated in reducing the functional capacity of HDL, which includes its ability to inhibit 11 
inflammation and promote cholesterol efflux (35-37). However, since the chronic low-grade 12 
inflammation found in metabolic disease and systemic infection are usually associated with low serum 13 
HDL-cholesterol, this suggests that inflammation that is localised in the gut, may have a unique effect 14 
in stimulating the synthesis of apo A-I and HDL. 15 
The evidence for an inverse association between intestinal permeability and serum TG (Figure 2C) 16 
was created largely by the data of participants with serum TG close to or above 1.5mmol/l. This is 17 
recognised as a critical threshold for serum TG, above which serum TG becomes associated with 18 
dyslipidaemia, dysglycaemia and insulin resistance (38). Because serum TG is regulated by many 19 
factors, it is possible that its concentration in serum, especially above 1.5mmol/l, may not be related 20 
directly to intestinal permeability, but acting as a marker for an as yet unidentified factor. An inverse 21 
association between intestinal permeability and serum TG also seems counterintuitive, especially in 22 
light of the evidence for increased intestinal permeability in type 2 diabetes (4).  23 
High-fat diets have consistently been linked with metabolic endotoxaemia and metabolic disease, 24 
partly due to the translocation of LPS across the enterocyte during chylomicron formation after fat-25 
feeding (39). Dietary saturated fat is also associated with increased serum HDL-cholesterol, possibly 26 
by stimulating the synthesis of apo A-I in the small intestine (40).  There was no evidence in the 27 
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present study of associations between the intake of saturated fat and gut permeability or inflammatory 1 
markers, but protein intake showed significant positive associations with LPS and sCD14, and a trend 2 
for an association with LBP. CD14 and LBP make-up integral parts of the LPS cellular receptor, 3 
increasing the likelihood of an LPS-induced pro-inflammatory cascade. Protein intake was also 4 
significantly associated with hsCRP, a clinical marker of immune activation. The products of the 5 
colonic proteolysis of dietary protein (ammonia and phenol) have been shown to impact on the 6 
expression of tight junction proteins, reducing gut barrier integrity in vitro (41). In humans, high 7 
phenol levels have been linked to disruption of the gut barrier (42), which provides evidence to 8 
implicate dietary protein as a possible cause of the local inflammation.  9 
 10 
 11 
CONCLUSION  12 
This study provides new evidence for significant variation in gut permeability in men without 13 
metabolic or gastrointestinal disease, but no evidence to support a link between this phenomenon and 14 
variation in serum LDL cholesterol.  The positive associations between increased gut permeability, 15 
serum HDL-cholesterol and LPS are consistent with HDL being an acute phase reactant to local 16 
gastrointestinal inflammation. These findings may have negative implications for the role of HDL as a 17 
biomarker of CVD risk, but need to be confirmed in future studies that measure acute phase reactants 18 
in HDL such as SAA, and HDL function. The potential for dietary macronutrients to be an underlying 19 
cause of this pro-inflammatory cascade is in accord with epidemiological evidence to link diet with 20 
metabolic disease through a putative, gut-dependent mechanism.  21 
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Table 1. Fasting metabolic markers showing bivariate correlation with serum HDL-cholesterol.  
*Data for LPS could not be normalised by log-transformation and so non-parametric analysis was used. 
 
 
  
 
 
Cohort mean 
(range) 
Low HDL 
(≤1.0mmol/l) 
n=9 
High HDL 
(>1.0mmol/l) 
n=21 
Between 
Group 
P-value 
Correlation 
with HDL (r) 
P 
Value 
HDL Cholesterol (mmol/l) 
 
BMI (kg/m2) 
 
1.26 (0.54-2.09) 
 
25.6 (19.5 – 36.2) 
0.87 (0.05) 
 
26.7 (1.21) 
 
1.44 (0.06) 
 
25.2 (0.96) 
 
<0.001 
 
ns 
 
 
-0.403 
 
 
0.027 
LDL Cholesterol (mmol/l) 
 
3.41 (1.98-4.96) 3.20 (0.25) 3.50 (0.16) ns -0.53 ns 
Total Cholesterol 
(mmol/l) 
5.12 (3.0-6.85) 4.58 (0.29) 5.35 (0.17) 0.026 0.430 0.018 
       
Fasting Triacylglycerol (mmol/l) 
 
0.98 (0.53-2.11) 1.08 (0.18) 0.90 (0.04) ns -0.251 ns 
Intestinal Permeability  
(% 0-6h 51Cr-EDTA recovery) 
 
Intestinal Permeability  
(% 6-24h 51Cr-EDTA recovery) 
 
1.40 (0.34 – 2.58) 
 
 
 
2.85 (1.11-5.03) 
1.08 (0.18) 
 
 
 
2.27 (0.26) 
1.54 (0.14) 
 
 
 
3.11 (0.20) 
0.056 
 
 
 
0.023 
0.392 
 
 
 
0.432 
0.032 
 
 
 
0.016 
Serum lipopolysaccharide 
(EU/mL) 
 
0.78 (0.25-1.8) 0.45 (0.15) 0.85 (0.07) 0.028* 0.410* 0.023 
Lipolysaccharide binding protein 
(µg/mL) 
 
11.2 (4.24-26.6) 10.4 (1.52) 11.4 (1.06) ns -0.082 ns 
sCD14 (µg/mL) 
 
1.06 (0.56-2.23) 0.99 (0.10) 1.09 (0.08) 
 
ns 0.231 ns 
Interleukin-6 (pg/mL) 
 
19.6 (0.3-91.55) 21.8 (7.32) 19.5 (4.55) 
 
ns 0.238 ns 
Tumour necrosis factor alpha 
(pg/mL) 
 
11.8 (5.0-72.21) 11.7 (2.88) 12.2(3.59) ns 0.099 ns 
hsCRP (mg/L) 2.26 (0.16-5.37) 1.21 (0.36) 2.75 (1.25) ns 
 
0.004 ns 
Fasting plasma glucose  
(mmol/l) 
 
 4.5 (0.12) 4.7 (0.14) ns 0.287 ns 
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Table 2 Univariate linear regression of anthropometric, dietary and metabolic variables with HDL-
Cholesterol as dependent variable, adjusted r2 = 0.875, p=0.10 
Co-variate B SE Beta P Value 
Age  -0.002 0.008 -0.41 0.797 
Weight  0.008 0.010 .295 0.446 
Waist Circumference -0.018 0.18 -0.565 0.366 
Systolic blood pressure  -0.025 0.16 -0.789 0.176 
Diastolic blood pressure  0.005 0.10 0.116 0.602 
Glucose  -0.251 0.147 -0.365 0.148 
NEFA  -0.091 0.286 -0.052 0.764 
Total cholesterol  0.330 0.083 0.757 0.010 
Triglyceride  -0.368 0.189 -0.343 0.110 
Lipopolysaccharide 0.231 0.081 0.431 0.036 
hsCRP -0.030 0.029 -0.378 0.346 
LBP -0.011 0.16 -0.129 0.532 
CD14 0.473 0.188 0.435 0.053 
IL-6 -0.007 0.002 -0.367 0.037 
TNF-α 0.019 0.009 0.700 0.087 
Insulin 0.038 0.012 0.797 0.027 
Dietary total carbohydrate -0.095 0.017 -1.557 0.003 
Dietary protein -0.122 0.042 -0.566 0.035 
Dietary fat -0.079 0.120 -1.219 0.001 
Dietary fibre -0.10 0.004 -0.242 0.068 
Alcohol intake 0.000 0.007 -0.010 0.954 
Small intestinal permeability 0.368 0.073 0.593 0.004 
Large intestinal permeability -0.266 0.182 -0.312 0.204 
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Figure Legends 
 
Figure 1A .  Bivariate correlation between intestinal permeability and fasting HDL cholesterol, n=30. 
Small intestine, 0-6h recovery (closed circle, solid line) r=0.389, p=0.032;  large intestine, 6-24h 
recovery (open circle, dashed line) r=0.372, p=0.043. 
 
Figure 1B. Bivariate correlation between intestinal permeability  and fasting LDL-cholesterol, n=30. 
Small intestine, 0-6h recovery (closed circle, solid line) r=-0.354, p=0.078; large intestine, 6-24h 
recovery (open circle, dashed line) r=0.065, p=0.622 
 
Figure 1C. Bivariate correlation between intestinal permeability and fasting plasma triglyceride, 
n=30.  Small intestine, 0-6h recovery (closed circle, solid line) r=-0.386, p=0.035; large intestine, 6-
24h recovery (open circle, dashed line) r=-0.205, p=0.278 
 
Figure 2A. Box plot of plasma lipopolysaccharide concentrations in non-diabetic men with low (≤ 
1mmol/l, n=9) or high (> 1mmol/l, n=21) HDL-cholesterol levels. Boxes represent the 25th and 75th 
percentiles, bands inside the box is the median, and the whiskers display the full ranges (from 
minimum to maximum), p=0.028. 
 
Figure 2B. Spearman’s coefficient of rank correlation between plasma HDL-cholesterol and plasma 
lipopolysaccharide concentration, n=30, p=0.023.  
 
